TapewireFind a company

person · Reporting owner

Gloria Melanie

Disclosed activity across 2 companies

Tapewire entity
20900
SEC CIK
0001973838

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACELYRIN, Inc.SLRN · Entity 79310Chief Operating OfficerMay 23, 2024May 24, 2024
Immunovant, Inc.IMVT · Entity 3632Chief Operating OfficerOctober 07, 2026October 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACELYRIN, Inc.

Report date May 23, 2024 · Filed May 24, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2034-05-22Direct184,042 Reported balance After 2024-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-05-23 · Grant · Acquired 184,042 · Balance 184,042

F1: 33% of the shares subject to the option vest on December 15, 2024, 34% of the shares subject to the option vest on June 15, 2025, and the remaining 33% of the shares subject to the option vest on December 15, 2025, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: 33% of the shares subject to the option vest on December 15, 2024, 34% of the shares subject to the option vest on June 15, 2025, and the remaining 33% of the shares subject to the option vest on December 15, 2025, subject to the Reporting Person's continued service.

Immunovant, Inc.

Report date October 07, 2026 · Filed October 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect217,060 Reported balance After 2026-10-07 transaction · row 1
1 source row

Row 1 · 2026-10-07 · Sale · Disposed 2,241 · Balance 217,060

F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 07, 2026 Filed Oct 9, 2026 21:04 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,241 $32.06 $71,846.46
Disclosure

SEC source: 0001764013-26-000112 · wk-form4_1791579845.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,060

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
August 20, 2026 Filed Aug 21, 2026 20:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 3,056 $44.16 $134,952.96
Disclosure

SEC source: 0001973838-26-000007 · wk-form4_1787342630.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,301

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on August 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.80 - $44.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 20:15 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 106 $39.99 $4,238.94
Disclosure

SEC source: 0001764013-26-000083 · wk-form4_1783714509.xml · nonDerivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,357

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 20:15 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,930 $39.53 $76,292.90
Disclosure

SEC source: 0001764013-26-000083 · wk-form4_1783714509.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,463

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 23:46 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,966 $38.95 $115,525.70
Disclosure

SEC source: 0001764013-26-000075 · wk-form4_1782517606.xml · nonDerivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,393

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.78 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 23:46 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 14,748 $38.18 $563,078.64
Disclosure

SEC source: 0001764013-26-000075 · wk-form4_1782517606.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,359

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
May 20, 2026 Filed May 22, 2026 20:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,698 $32.95 $55,949.10
Disclosure

SEC source: 0001764013-26-000067 · wk-form4_1779480209.xml · nonDerivative · entry 3

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,107

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.55 - $33.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
May 20, 2026 Filed May 22, 2026 20:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,168 $32.15 $37,551.20
Disclosure

SEC source: 0001764013-26-000067 · wk-form4_1779480209.xml · nonDerivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,805

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 - $32.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
May 20, 2026 Filed May 22, 2026 20:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 249 $30.41 $7,572.09
Disclosure

SEC source: 0001764013-26-000067 · wk-form4_1779480209.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,973

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.32 - $31.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 20:03 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 8,722 $24.83 $216,567.26
Disclosure

SEC source: 0001973838-26-000004 · wk-form4_1775851435.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,222

F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:20 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 121,063 $0.00 Strike: $24.61 $0.00
Disclosure

SEC source: 0001764013-26-000040 · wk-form4_1775766037.xml · derivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,063

Underlying: Common Stock · 121,063 shares

Expires 2036-04-07

F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:20 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 83,671 $0.00 $0.00
Disclosure

SEC source: 0001764013-26-000040 · wk-form4_1775766037.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,944

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:07 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 942 $28.90 $27,223.80
Disclosure

SEC source: 0001764013-26-000013 · wk-form4_1772226458.xml · nonDerivative · entry 3

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,273

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 - $29.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:07 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 859 $28.16 $24,189.44
Disclosure

SEC source: 0001764013-26-000013 · wk-form4_1772226458.xml · nonDerivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,215

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 - $28.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:07 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,437 $26.98 $38,770.26
Disclosure

SEC source: 0001764013-26-000013 · wk-form4_1772226458.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,074

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 - $27.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 20, 2025 Filed Nov 21, 2025 21:24 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 2,375 $23.97 $56,928.75
Disclosure

SEC source: 0001764013-25-000156 · wk-form4_1763760245.xml · nonDerivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,511

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 27,489 of these RSUs vested on November 18, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.93 - $24.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 20, 2025 Filed Nov 21, 2025 21:24 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 10,251 $23.54 $241,308.54
Disclosure

SEC source: 0001764013-25-000156 · wk-form4_1763760245.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,886

F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 27,489 of these RSUs vested on November 18, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.93 - $23.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:53 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 107,297 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000057 · wk-form4_1743713606.xml · derivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,297

Underlying: Common Stock · 107,297 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:53 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 76,181 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000057 · wk-form4_1743713606.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,137

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
November 18, 2024 Filed Nov 20, 2024 22:15 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 137,446 $0.00 Strike: $25.51 $0.00
Disclosure

SEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · derivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,446

Underlying: Common Stock · 137,446 shares

Expires 2034-11-18

F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
November 18, 2024 Filed Nov 20, 2024 22:15 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 109,956 $0.00 $0.00
Disclosure

SEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,956

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
May 23, 2024 Filed May 24, 2024 23:06 UTC ACELYRIN, Inc. SLRN · Entity 79310 GrantEmployee Stock Option (right to buy) · Derivative 184,042 $0.00 Strike: $4.22 $0.00
Disclosure

SEC source: 0001962918-24-000067 · wk-form4_1716591959.xml · derivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,042

Underlying: Common Stock · 184,042 shares

Expires 2034-05-22

F1 · derivative.exercise_date: 33% of the shares subject to the option vest on December 15, 2024, 34% of the shares subject to the option vest on June 15, 2025, and the remaining 33% of the shares subject to the option vest on December 15, 2025, subject to the Reporting Person's continued service.

Read SEC document
May 15, 2024 Filed May 17, 2024 23:12 UTC ACELYRIN, Inc. SLRN · Entity 79310 Tax withholdingCommon Stock 10,298 $4.47 $46,032.06
Disclosure

SEC source: 0001962918-24-000063 · wk-form4_1715987559.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,286

F1 · shares: Represents the total number of shares withheld to settle the Reporting Person's tax liability for the Restricted Stock Units that vested on May 15, 2024.

Read SEC document
January 09, 2024 Filed Jan 11, 2024 23:31 UTC ACELYRIN, Inc. SLRN · Entity 79310 GrantEmployee Stock Option (right to buy) · Derivative 494,297 $0.00 Strike: $7.68 $0.00
Disclosure

SEC source: 0001962918-24-000006 · wk-form4_1705015852.xml · derivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 494,297

Underlying: Common Stock · 494,297 shares

Expires 2034-01-08

F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Read SEC document
August 16, 2023 Filed Aug 18, 2023 22:50 UTC ACELYRIN, Inc. SLRN · Entity 79310 GrantCommon Stock 140,584 $0.00 $0.00
Disclosure

SEC source: 0001962918-23-000022 · wk-form4_1692399025.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,584

F1 · shares: Represents Restricted Stock Units (RSUs). 1/4 of the RSUs will vest on May 15, 2024 and the remaining RSUs will vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
May 09, 2023 Filed May 12, 2023 00:56 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherEmployee Stock Option (right to buy) · Derivative 232,436 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 6

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,436

Underlying: Common Stock · 232,436 shares

Expires 2033-05-03

F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document
May 09, 2023 Filed May 12, 2023 00:56 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherEmployee Stock Option (right to buy) · Derivative 232,436 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 5

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 232,436 shares

Expires 2033-05-03

F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document
May 09, 2023 Filed May 12, 2023 00:56 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherEmployee Stock Option (right to buy) · Derivative 187,988 $0.00 Strike: $5.88 $0.00
Disclosure

SEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 4

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,988

Underlying: Common Stock · 187,988 shares

Expires 2032-11-20

F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 17, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document
May 09, 2023 Filed May 12, 2023 00:56 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherEmployee Stock Option (right to buy) · Derivative 187,988 $0.00 Strike: $5.88 $0.00
Disclosure

SEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 3

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 187,988 shares

Expires 2032-11-20

F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 17, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document
May 09, 2023 Filed May 12, 2023 00:56 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherEmployee Stock Option (right to buy) · Derivative 330,181 $0.00 Strike: $4.04 $0.00
Disclosure

SEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,181

Underlying: Common Stock · 330,181 shares

Expires 2032-01-19

F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on November 8, 2022 and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document
May 09, 2023 Filed May 12, 2023 00:56 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherEmployee Stock Option (right to buy) · Derivative 330,181 $0.00 Strike: $4.04 $0.00
Disclosure

SEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 330,181 shares

Expires 2032-01-19

F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on November 8, 2022 and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document
May 04, 2023 Filed May 5, 2023 00:03 UTC ACELYRIN, Inc. SLRN · Entity 79310 GrantEmployee Stock Option (right to buy) · Derivative 232,436 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-23-027518 · doc4.xml · derivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,436

Underlying: Class A Common Stock · 232,436 shares

Expires 2033-05-03

F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.